CJC-1295 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Prem Narain Saxena (15 October 1925 – 29 November 1999) was the Founder Professor and Chairman of the Department of Pharmacology, Jawaharlal Nehru Medical College, India. He made contributions to the fields of traditional medicine and neuropharmacology. His demonstration of the wound-healing property of Curcuma longa was a major contributor to India's successful challenge of the US patent on the wound-healing property of Haldi. He was involved in discovery and pre-clinical development of the non-barbiturate hypnotic Methaqualone. His basic studies have helped in understanding the role of various neurotransmitters in thermoregulation. He also standardized the use of Setaria cervi for discovery of new anti-filarial agents.
==== Microparticle and nanoparticle synthesis ==== Advanced particles and particle-based materials, such as polymer particles, microcapsules, nanocrystals, and photonic crystal clusters or beads can be synthesized with the assistance of droplet-based microfluidics. Nanoparticles, such as colloidal CdS and CdS/CdSe core-shell nanoparticles, can also be synthesized through multiple steps on a millisecond time scale in a microfluidic droplet-based system. Nanoparticles, microparticles and colloidal clusters in microfluidic devices are useful for functions such as drug delivery. The first particles incorporated in droplet-based systems were silica gels in the micrometer size range in order to test their applications in the manufacturing of displays and optical coatings. Mixing solid particles with aqueous microdroplets requires changes to microfluidic channels such as additional reagent mixes and choice of specific materials such as silica or polymers that do not interfere with the channels and any bioactive substances the droplets contain. The synthesis of copolymers requires milling macroscopic molecules to microparticles with porous, irregular surfaces using organic solvents and emulsification techniques. These droplets preloaded with microparticles can also be quickly processed using UV irradiation. Characterization of these microparticles and nanoparticles involves microimaging for analyzing the structure and the identification of the macroscopic material being milled.
=== Canada === Health Canada classifies VOCs as organic compounds that have boiling points roughly in the range of 50 to 250 °C (122 to 482 °F). The emphasis is placed on commonly encountered VOCs that would have an effect on air quality.
Materials science is an interdisciplinary field concerned with understanding the relationships between the structure of materials and their properties and using this knowledge to design materials for specific applications. The internal structure of a material—from atomic arrangements to microscopic features—strongly influences its mechanical, electrical, thermal, and optical behavior. In engineering practice, materials science and engineering are often described through the processing–structure–properties–performance paradigm, in which processing determines structure, structure determines properties, and properties ultimately control the performance of a material in service. The intellectual origins of materials science stem from the Age of Enlightenment, when researchers began to use analytical thinking from chemistry, physics, and engineering to understand ancient, phenomenological observations in metallurgy and mineralogy. Materials science still incorporates elements of physics, chemistry, and engineering. As such, the field was long considered by academic institutions as a sub-field of these related fields. Beginning in the 1940s, materials science began to be more widely recognized as a specific and distinct field of science and engineering, and major technical universities around the world created dedicated schools for its study. By studying how the history of a material (processing) influences its structure, properties, and performance, materials scientists have made many contributions to new technologies in biomaterials, metallurgy, and nanotechnology.
Sources: en.wikipedia.org
Naloxone works by temporarily blocking the effects of opioids, including respiratory depression and sedation. Naloxone is safe and side effects are rare, generally limited to allergic reactions. It should be given if there is any suspicion of an opioid overdose. Naloxone is available to the public in the United States in two routes of administration: intranasal and intramuscular/subcutaneous. Intranasal forms include Narcan, approved in 2015, and Kloxxado, approved in 2021. Formulations that are injectable into the intramuscular or subcutaneous spaces include Evzio, approved in 2014, and Zimhi, approved in 2021. The doses are approved for both children and adults and may be repeated every 2–3 minutes. Synthetic opioids like fentanyl and carfentanil are much more potent than prescription opioids and heroin. There is some debate about whether increased doses of naloxone are required to reverse overdose from synthetic opioids; however, this concern has prompted FDA approval of higher dose naloxone formulations such as Kloxxado and Zimhi. The effects of naloxone last for approximately 30-90 minutes, at which point opioids present in the body may begin to take effect again depending on the specific opioids duration of action. Therefore, transport to a hospital is indicated after naloxone administration, and the medication may need to be re-administered.
Bisoprolol is used for prevention of cardiovascular events following a heart attack in patients with risk factors for disease progression, in the management of congestive heart failure with reduced ejection fraction, and as a second-line agent for hypertension. Bisoprolol may be beneficial in the treatment of high blood pressure, but it is not recommended as a first-line antihypertensive agent. It can be an adjunct to first-line antihypertensive agents in patients with accompanying comorbidities, for example, congestive heart failure, where selected beta blockers can be added in patients who remain mildly to moderately symptomatic despite appropriate doses of an angiotensin-converting-enzyme inhibitor. In cardiac ischemia, the drug is used to reduce the activity of the heart muscle, thereby reducing its oxygen and nutrient demands and allowing its reduced blood supply to still transport sufficient amounts of oxygen and nutrients to meet its needs.
=== Magnetic confinement fusion === In fusion devices, such as tokamaks and stellarators, ICRH antennas are installed in the machine vessel to heat the plasma using radio waves with frequencies in the range of the ion cyclotron resonance. ICRH provides localized heating of ions in fusion plasmas, which can generate a large population of energetic particles typically inaccessible with other heating methods (such as electron cyclotron resonance heating or neutral beam injection). The confinement properties of fast ions in plasma is a major research topic in fusion plasma physics.
Perhaps the earliest of these sutras, the Aṣṭasāhasrikā Prajñāpāramitā, contains a passage which describes the suchness (tathatā) of dharmas using various terms including shūnyatā, cessation (nirodha) and unarisen (anutpāda). Most famously, the Heart Sutra states:Sariputra, in that way, all phenomena are empty, that is, without characteristic, unproduced, unceased, stainless, not stainless, undiminished, unfilled.The Heart Sutra also negates the 12 links of dependent origination: "There is no ignorance, no extinction of ignorance, up to and including no aging and death and no extinction of aging and death." Some Mahāyāna sūtras present the insight into the non-arisen nature of dharmas as a great achievement of bodhisattvas.
He received the Hirschmann Award in Peptide Chemistry from the American Chemical Societyin 1994, the (inaugural) Kaiser Award from the Protein Society in 2002, the du Vigneaud Award from the American Peptide Society (2004), the 2009 Merrifield award from the American Peptide Society, the Rudinger Medal from the European Peptide Society (2010), the Akabori Medal from the Japanese Peptide Society (2010), the Bader Award in Bioorganic Chemistry (2011) from the American Chemical Society, the Leach Medal from the Lorne Protein Conference (2013), the Prelog Medal from the ETH Zurich (2017), the (inaugural) Scoffone Award from the Italian Peptide Society (2018), and the Meienhofer Award of the Boulder Peptide Society (2022). Dr. Kent is Honorary Fellow of the Royal Society of New Zealand. He was elected Fellow of the American Association for the Advancement of Science in 2000, and Fellow of the Royal Society of Chemistry in 2008. In May 2016 the Journal of Peptide Science, edited by Luis_Moroder, published a Festschrift in celebration of Stephen Kent's 70th birthday. In 2022, Stephen Kent's scientific autobiography was published as the first English language contribution to the book series Lives-in-Chemistry; this series is steered by an Advisory Board appointed by the Executive Committee of the Fachgruppe Geschichte der Chemie (History of Chemistry Division) of the Gesellschaft Deutscher Chemiker (GDCh).
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.